AIA
GILD icon

Affinity Investment Advisors’s Gilead Sciences GILD Stock Holding History

Affinity Investment Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
16,149
+251
+2% +$35.1K 1.41% 17
2025
Q4 		$1.95M Sell
15,898
-2,643
-14% -$321K 1.3% 22
2025
Q3 		$2.06M Sell
18,541
-391
-2% -$44.4K 1.39% 20
2025
Q2 		$2.1M Buy
18,932
+5,898
+45% +$628K 1.59% 14
2025
Q1 		$1.46M Hold
13,034
– – 1.19% 22
2024
Q4 		$1.2M Sell
13,034
-6,940
-35% -$625K 1% 35
2024
Q3 		$1.67M Buy
19,974
+385
+2% +$29.4K 1.15% 27
2024
Q2 		$1.34M Sell
19,589
-1,997
-9% -$133K 1.01% 35
2024
Q1 		$1.58M Buy
21,586
+2,640
+14% +$203K 1.15% 31
2023
Q4 		$1.53M Buy
18,946
+157
+0.8% +$12.2K 1.04% 28
2023
Q3 		$1.41M Sell
18,789
-1,050
-5% -$80.8K 0.91% 29
2023
Q2 		$1.53M Sell
19,839
-1,622
-8% -$129K 0.89% 34
2023
Q1 		$1.78M Sell
21,461
-8,465
-28% -$701K 0.95% 25
2022
Q4 		$2.57M Sell
29,926
-2,337
-7% -$185K 1.18% 19
2022
Q3 		$1.99M Sell
32,263
-270
-0.8% -$17K 1.03% 26
2022
Q2 		$2.01M Buy
32,533
+4,118
+14% +$255K 0.98% 28
2022
Q1 		$1.69M Buy
28,415
+361
+1% +$23.1K 0.69% 44
2021
Q4 		$2.04M Buy
28,054
+2,063
+8% +$142K 0.82% 37
2021
Q3 		$1.81M Sell
25,991
-2,432
-9% -$171K 0.81% 39
2021
Q2 		$1.96M Sell
28,423
-15,652
-36% -$1.05M 0.88% 41
2021
Q1 		$2.85M Sell
44,075
-358
-0.8% -$23.1K 1.04% 34
2020
Q4 		$2.59M Buy
44,433
+2,593
+6% +$156K 1.04% 35
2020
Q3 		$2.64M Buy
41,840
+25,040
+149% +$1.74M 1.16% 36
2020
Q2 		$1.29M Buy
+16,800
New +$1.29M 0.61% 55
2017
Q2 		– Sell
-152,679
Closed -$10.4M – 179
2017
Q1 		$10.4M Sell
152,679
-6,548
-4% -$460K 0.94% 48
2016
Q4 		$11.4M Sell
159,227
-15,489
-9% -$1.15M 1.07% 43
2016
Q3 		$13.8M Sell
174,716
-18,739
-10% -$1.52M 1.17% 36
2016
Q2 		$16.1M Buy
193,455
+11,571
+6% +$1.03M 1.19% 33
2016
Q1 		$16.7M Buy
181,884
+101,303
+126% +$9.14M 1.47% 26
2015
Q4 		$8.15M Buy
80,581
+2,093
+3% +$218K 0.7% 55
2015
Q3 		$7.71M Buy
78,488
+13,515
+21% +$1.5M 0.7% 55
2015
Q2 		$7.61M Sell
64,973
-12,546
-16% -$1.37M 0.61% 58
2015
Q1 		$7.61M Buy
77,519
+723
+0.9% +$73.4K 0.55% 64
2014
Q4 		$7.24M Sell
76,796
-502
-0.6% -$51.9K 0.67% 59
2014
Q3 		$8.23M Sell
77,298
-6,933
-8% -$679K 0.83% 56
2014
Q2 		$6.98M Sell
84,231
-962
-1% -$74.9K 0.79% 54
2014
Q1 		$6.04M Buy
85,193
+9,092
+12% +$713K 0.71% 54
2013
Q4 		$5.71M Buy
76,101
+1,445
+2% +$101K 0.7% 55
2013
Q3 		$4.69M Buy
+74,656
New +$4.46M 0.61% 55

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Affinity Investment Advisors's GILD Position: Q1 2026 in Review

Affinity Investment Advisors increased its Gilead Sciences (GILD) stake by 1.6% in Q1 2026, buying an estimated $35.1K and bringing the position to 16,149 shares worth $2.25M. The position accounts for 1.41% of the portfolio, ranked #17.

Affinity Investment Advisors first reported a position in GILD in Q3 2013 and has held it in 39 quarters since. The position peaked at $16.7M in Q1 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Affinity Investment Advisors held 16,149 shares of Gilead Sciences worth $2.25M as of Q1 2026.
  • Affinity Investment Advisors bought 251 Gilead Sciences shares in Q1 2026, an estimated $35.1K.
  • Gilead Sciences made up 1.41% of Affinity Investment Advisors's portfolio in Q1 2026, its #17 holding.
  • Affinity Investment Advisors first reported a position in Gilead Sciences in Q3 2013 and has held it in 39 quarters since.
  • Affinity Investment Advisors's Gilead Sciences position peaked at $16.7M in Q1 2016.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Affinity Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.